{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:47:25Z","timestamp":1765079245222},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T00:00:00Z","timestamp":1381536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10198-013-0534-8","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T17:54:40Z","timestamp":1381514080000},"page":"917-925","source":"Crossref","is-referenced-by-count":10,"title":["Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain"],"prefix":"10.1007","volume":"15","author":[{"given":"\u00c1lvaro","family":"Hidalgo-Vega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Ramos-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Villoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,12]]},"reference":[{"issue":"Suppl. 2","key":"534_CR1","first-page":"S2","volume":"19","author":"J Lopez-Sendon","year":"2012","unstructured":"Lopez-Sendon, J.: Chronic stable angina guidelines: is there an emerging international consensus? Br J Cardiol 19(Suppl. 2), S2\u2013S11 (2012)","journal-title":"Br J Cardiol"},{"issue":"15","key":"534_CR2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden, W.E.: Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med 356(15), 1503\u20131516 (2007)","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"534_CR3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-012-0005-z","volume":"73","author":"GM Keating","year":"2013","unstructured":"Keating, G.M.: Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs 73(1), 55\u201373 (2013)","journal-title":"Drugs"},{"issue":"4","key":"534_CR4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/hrt.81.4.352","volume":"81","author":"N Brown","year":"1999","unstructured":"Brown, N., Melville, M., Gray, D., Young, T., Munro, J., Skene, A.M., et al.: Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population. Heart 81(4), 352\u2013358 (1999)","journal-title":"Heart"},{"issue":"2","key":"534_CR5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/heart.87.2.140","volume":"87","author":"B Brorsson","year":"2002","unstructured":"Brorsson, B., Bernstein, S.J., Brook, R.H., Werko, L.: Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 87(2), 140\u2013145 (2002)","journal-title":"Heart"},{"issue":"4","key":"534_CR6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/CIRCOUTCOMES.108.829523","volume":"2","author":"SV Arnold","year":"2009","unstructured":"Arnold, S.V., Morrow, D.A., Lei, Y., Cohen, D.J., Mahoney, E.M., Braunwald, E., et al.: Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2(4), 344\u2013353 (2009)","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"16","key":"534_CR7","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archinternmed.2009.295","volume":"169","author":"JF Beltrame","year":"2009","unstructured":"Beltrame, J.F., Weekes, A.J., Morgan, C., Tavella, R., Spertus, J.A.: The prevalence of weekly angina among patients with chronic stable angina in primary care practices: the Coronary Artery Disease in General Practice (CADENCE) Study. Arch. Intern. Med 169(16), 1491\u20131499 (2009)","journal-title":"Arch. Intern. Med"},{"issue":"12","key":"534_CR8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/archinte.168.12.1310","volume":"168","author":"TM Maddox","year":"2008","unstructured":"Maddox, T.M., Reid, K.J., Spertus, J.A., Mittleman, M., Krumholz, H.M., Parashar, S., et al.: Angina at 1\u00a0year after myocardial infarction: prevalence and associated findings. Arch. Intern. Med 168(12), 1310\u20131316 (2008)","journal-title":"Arch. Intern. Med"},{"issue":"20","key":"534_CR9","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","volume":"61","author":"M Kosiborod","year":"2013","unstructured":"Kosiborod, M., Arnold, S.V., Spertus, J.A., McGuire, D.K., Li, Y., Yue, P., et al.: Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects with Chronic Stable Angina). J. Am. Coll. Cardiol 61(20), 2038\u20132045 (2013)","journal-title":"J. Am. Coll. Cardiol"},{"key":"534_CR10","unstructured":"EMEA. EPAR for Ranexa. Available at: http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/ranexa\/ranexa.htm . Updated on Sep 14th, 2009"},{"issue":"Supl D","key":"534_CR11","first-page":"9","volume":"7","author":"JJ Alonso","year":"2007","unstructured":"Alonso, J.J., Bueno, H.: Angina de pecho estable. Trascendencia cl\u00ednica en la era de la intervenci\u00f3n, limitaciones y avances actuales de su terapia farmacol\u00f3gica. Rev. Esp. Cardiol 7(Supl D), 9\u201318 (2007)","journal-title":"Rev. Esp. Cardiol"},{"issue":"8","key":"534_CR12","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","volume":"43","author":"B Chaitman","year":"2004","unstructured":"Chaitman, B., Skettino, S., Parker, J., Hanley, P., Meluzin, J., Kuch, J., et al.: Anti-ischemia effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43(8), 1375\u20131382 (2004)","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"534_CR13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"B Chaitman","year":"2004","unstructured":"Chaitman, B., Pepine, C., Parker, J., Skopal, J., Chumakova, G., Kuch, J., et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 291(3), 309\u2013316 (2004)","journal-title":"JAMA"},{"key":"534_CR14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","volume":"48","author":"PHGN Stone","year":"2006","unstructured":"Stone, P.H.G.N., Blokhin, A., et al.: Anti-anginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J. Am. Coll. Cardiol 48, 566\u2013575 (2006)","journal-title":"J. Am. Coll. Cardiol"},{"issue":"2","key":"534_CR15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.108.798009","volume":"1","author":"SV Arnold","year":"2008","unstructured":"Arnold, S.V., Morrow, D.A., Wang, K., Lei, Y., Mahoney, E.M., Scirica, B.M., Braunwald, E., Cohen, D.J., MERLIN-TIMI 36 Investigators: Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes 1(2), 107\u2013115 (2008). Epub 2008 Nov 5","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"16","key":"534_CR16","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","volume":"297","author":"DA Morrow","year":"2007","unstructured":"Morrow, D.A., Scirica, B.M., Karwatowska-Prokopczuk, E.: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297(16), 1775\u20131783 (2007)","journal-title":"JAMA"},{"issue":"3","key":"534_CR17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","volume":"43","author":"JW Shaw","year":"2005","unstructured":"Shaw, J.W., Johnson, J.A., Coons, S.J.: US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43(3), 203\u2013220 (2005)","journal-title":"Med Care"},{"issue":"3","key":"534_CR18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2011.11.003","volume":"133","author":"S Sossalla","year":"2012","unstructured":"Sossalla, S., Maier, L.S.: Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther 133(3), 311\u2013323 (2012)","journal-title":"Pharmacol Ther"},{"issue":"3","key":"534_CR19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF03320519","volume":"11","author":"C Lucioni","year":"2009","unstructured":"Lucioni, C., Mazzi, S.: Una valutazione economica di ranolazina add-on nel trattamento dell\u2032angina stabile cronica. Pharmaco Econ Italian Res Art 11(3), 141\u2013152 (2009)","journal-title":"Pharmaco Econ Italian Res Art"},{"issue":"3","key":"534_CR20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/europace\/eus400","volume":"15","author":"E Karwatowska-Prokopczuk","year":"2013","unstructured":"Karwatowska-Prokopczuk, E., Wang, W., Cheng, M.L., Zeng, D., Schwartz, P.J., Belardinelli, L.: The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. Europace 15(3), 429\u2013436 (2013)","journal-title":"Europace"},{"key":"534_CR21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.18553\/jmcp.2005.11.4.300","volume":"11","author":"L Etemad","year":"2005","unstructured":"Etemad, L., McCollam, P.: Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm 11, 300\u2013306 (2005)","journal-title":"J Manag Care Pharm"},{"key":"534_CR22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0735-1097(94)00397-9","volume":"25","author":"JA Spertus","year":"1995","unstructured":"Spertus, J.A., Winder, J.A., Dewhurst, T.A., et al.: Development and evaluation of the Seattle angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 25, 333\u2013341 (1995)","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"534_CR23","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1157\/13092800","volume":"59","author":"K Fox","year":"2006","unstructured":"Fox, K., Garcia, M.A., Ardissino, D., Buszman, P., Camici, P.G., Crea, F., et al.: Guidelines on the management of stable angina pectoris. Executive summary. Rev Esp Cardiol 59(9), 919\u2013970 (2006)","journal-title":"Rev Esp Cardiol"},{"key":"534_CR24","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos (2010) Base de datos del medicamento. Disponible en: http:\/\/www.portalfarma.com\/pfarma\/espacioges.nsf\/wfAccesoEspacioGestion?OpenForm (consultado abril 2010)"},{"key":"534_CR25","unstructured":"Ministerio de Sanidad y Pol\u00edtica Social (2010) Informaci\u00f3n sobre los productos incluidos en la prestaci\u00f3n farmac\u00e9utica del SNS (dispensables a trav\u00e9s de oficinas de farmacia). Disponible en: http:\/\/www.msc.es\/profesionales\/farmacia\/frmNomenclator.jsp (consultado abril 2010)"},{"key":"534_CR26","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/eurheartj\/ehi109","volume":"26","author":"C Daly","year":"2005","unstructured":"Daly, C., Clemens, F., Lopez Sendon, J., Tavazzi, L., Boersma, E., Danchin, N., et al.: The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 26, 1011\u20131022 (2005)","journal-title":"Eur Heart J"},{"key":"534_CR27","unstructured":"Oblikue Consulting (2010) eSalud: Base de datos de informaci\u00f3n econ\u00f3mica del sistema sanitario. Disponible en http:\/\/oblikuecom\/bddcostes\/ (consultado junio 2010)"},{"key":"534_CR28","unstructured":"Ministerio de Sanidad y Consumo (2010) Explotaci\u00f3n del CMBD 2008. http:\/\/www.msc.es\/estadEstudios\/estadisticas\/cmbd.htm (consultado en junio de 2010)"},{"key":"534_CR29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10198-005-0309-y","volume":"6","author":"I Longworth","year":"2005","unstructured":"Longworth, I., Bluxton, M., Sculpher, M.: Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ 6, 347\u2013353 (2005)","journal-title":"Eur J Health Econ"},{"key":"534_CR30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.39129.442164.55","volume":"334","author":"S Griffin","year":"2007","unstructured":"Griffin, S., Barber, J., Manca, A.: Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. British Med J 334, 624\u2013628 (2007)","journal-title":"British Med J"},{"key":"534_CR31","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economics","author":"A Briggs","year":"2006","unstructured":"Briggs, A., Sculpher, M., Claxton, K.: Decision modelling for health economics. Oxford University Press, Oxford (2006)"},{"issue":"3","key":"534_CR32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/(SICI)1099-1050(199905)8:3<269::AID-HEC425>3.0.CO;2-D","volume":"8","author":"K Claxton","year":"1999","unstructured":"Claxton,\u00a0 K.: Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ 8(3), 269\u2013274 (1999)","journal-title":"Health Econ"},{"issue":"4","key":"534_CR33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","volume":"16","author":"J Sacrist\u00e1n","year":"2002","unstructured":"Sacrist\u00e1n, J., Oliva, J., Del Llano, J., Prieto, L., Pinto, J.: What is an efficient health technology in Spain? Gac Sanit 16(4), 334\u2013343 (2002)","journal-title":"Gac Sanit"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-013-0534-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-013-0534-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-013-0534-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T16:17:18Z","timestamp":1716049038000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-013-0534-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,12]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s10198-013-0534-8","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,12]]}}}